-
kalydeco-vertex-pharmaceuticals-australia-pty-ltd-1 "
Kalydeco Product information".
Health Canada. 25
April 2012.
Retrieved 31 May 2022. "
Kalydeco- ivacaftor...
- States. On 31
January 2012,
Vertex gained FDA
approval of the
first drug,
Kalydeco, to
treat the
underlying cause of
cystic fibrosis rather than the symptoms...
- inhibitor; telaprevir, a
protease inhibitor for
treatment of
hepatitis C; and
Kalydeco, for the
treatment of
cystic fibrosis. In 2003,
Vertex was
listed as one...
- Disposition. 10 (4): 397–409. doi:10.1002/bdd.2510100407. PMID 2547465. "
Kalydeco: EPAR –
Product Information" (PDF).
European Medicines Agency. 12 May 2021...
-
development and use of five FDA-approved therapies,
including ivacaftor (
Kalydeco). The
latest FDA
approved drug is Trikafta,
which was p****ed by the FDA...
-
development of the drug that
twenty years later (January 2012) was
approved as
Kalydeco.
Unlike other drugs that were
available that just
address symptoms of CF...
-
efforts to find
treatments for
related conditions.
Ivacaftor (brand name
Kalydeco,
developed as VX-770) is a
medication approved by the FDA in 2012, for...
- drug is
being developed by Novartis. Like
ivacaftor (which is
marketed as
Kalydeco),
icenticaftor functions by
acting as a
stimulator of the
protein cystic...
-
kalafungin (INN)
Kalbitor Kaletra Kalexate kallidinogenase (INN)
Kalliga Kalydeco kanamycin (INN)
Kanjinti Kantrex Kanuma Kaon Cl-10 Kaon Cl
Kapidex Kappadione...
- from 2012 to 2020.
Under his leadership,
Vertex developed and
launched Kalydeco, Orkambi,
Symdeko and
Trikafta – the
first medicines to
treat the underlying...
